Older adults with diabetes using GLP-1 receptor agonist medications may face increased risk of serious eye conditions, study ...

GLP-1 RA therapy reduces hidradenitis suppurativa severity, flares, symptoms, and BMI in patients with hidradenitis ...

Sara H. Jodka of Dickinson Wright PLLC discusses the legal landscape surrounding GLP-1 programs for weight loss, in light of ...

GLP-1 receptor agonists such as the popular weight loss/diabetes therapies Mounjaro, developed by Eli Lilly (NYSE:LLY), and ...

Patients with type 2 diabetes and atopic dermatitis show higher risk for cardiovascular events, but GLP-1 agonists reduce the ...

Rarely, GLP-1 agonists can cause a condition called acute pancreatitis, which is when your pancreas gets inflamed. When you have pancreatitis, you typically have severe abdominal pain that ...

For individuals with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a slightly increased risk for incident diabetic retinopathy (DR) and with a ...

The findings suggest that while GLP-1 RAs may slightly raise the risk of developing diabetic retinopathy, they do not ...

GLP-1 receptor agonists may reduce risk for obesity-related cancers among people with diabetes compared with dipeptidyl peptidase-4 inhibitors, according to findings scheduled for presentation at ...

Serena Williams says she has lost weight using GLP-1 medication. The drugs help manage blood sugar and promote weight loss, ...

The only safety endpoint associated with GLP-1 receptor agonist use was a 49% increased risk of diabetic retinopathy (aHR, 1.49; 1.11-2.00; P =.008).

GLP-1 receptor agonists are linked to a 55% reduction in mortality risk in women with ovarian cancer, based on a retrospective cohort study. The study utilized data from the TriNetX Research ...